Surgical Challenges After Neoadjuvant Therapy.

Neoadjuvant chemoimmunotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor are associated with excellent outcomes for patients with early-stage and resectable non-small cell lung cancer. Although they demonstrate increased patholog…

Preview only. Read the full abstract at the source